These are aromatase inhibitors (reduces circulating estrogen, thus acts on the ER stimulus), but also antiestrogens classified as SERMs or SERDs (directly inhibits the ER with the first orally administered SERD elacestrant being approved for BC treatment) [251,253]. The gene discussed is CYP19A1; the disease is breast cancer.